Exelixis, Inc. (Nasdaq: EXEL) today announced results from the final analysis of the dual primary endpoint of overall survival (OS) in the subset of patients without active liver metastases (non-liver...
– CABOMETYX significantly reduced the risk of disease progression or death by 74% and 60% in patients with non-functional and functional advanced NET, respectively, versus placebo –
- Presentations to be webcast on www.exelixis.com -
Exelixis (NASDAQ:EXEL) remains focused on expanding its CABO franchise while preparing for potential launches and data readouts tied to zanzalintinib, Andrew Peters, the company’s senior vice president...
– Findings in neuroendocrine tumors, kidney cancer, advanced colorectal cancer and other tumors to be presented –
– Merck to supply KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), the company’s subcutaneous anti-PD-1 therapy, for planned STELLAR-316 trial –
- Presentations to be webcast on www.exelixis.com -
- Total Revenues of $610.8 million, Cabozantinib Franchise U.S. Net Product Revenues of $555.0 million - - GAAP Diluted...
Barchart Research What to Expect from EXEL Earnings EXEL Generated May 4, 2026 Current Price $44.17 EPS Estimate $$0.67 Consensus Rating Moderate Buy Average Move 9.60% Exelixis Reports Tomorrow With Competitive...